1. At a Glance

Scarnose International Ltd (recently renamed Devi Lifecare Ltd, but we’ll keep calling it Scarnose for sanity) is a ₹19.8 crore market-cap SME stock trading at ₹62.8, which means the market currently values every rupee of its modest profit like it’s artisanal saffron. The latest half-year numbers show sales of ₹8.15 crore and PAT of ₹0.08 crore, translating to an EPS of ₹0.25 for H1 FY26. Annualise that (because yes, these are Half Yearly Results, not quarterly), and you get ₹0.50 EPS. At current price, the recalculated P/E is ~126x, not the polite 86x headline number people quote without checking result periodicity. ROCE is a sleepy 2.59%, ROE is 1.97%, debt is zero, and promoter holding is—brace yourself—0%. Three-month return is a mild +2.38%, one-year return is a brutal -61.9%, and five-year sales growth is effectively flat. This is a company that wants to be everywhere—pharma, animal health, hygiene, fertilizers—but currently earns like it’s running a neighbourhood wholesale desk with Excel 2007. Curious already? Good. Keep reading.

2. Introduction

Let’s start with the identity crisis. Scarnose International Ltd was incorporated in 2011 and originally described itself as being in Animal Food Products. Fast-forward to FY25, and the company amended its Memorandum of Association to include APIs, oncology drugs, antibiotics, vaccines, cosmetics, personal hygiene products, fertilizers, agri-chemicals, ayurvedic to allopathic formulations, and basically anything that can be packed in a bottle, blister, or bag. If diversification were a yoga pose, this would be advanced-level contortion.

The timing is interesting. FY25 saw the company approving related-party transactions of ₹100 crore each with two entities—M/s Dada Organics Limited and M/s Dadaji Lifescience Private Limited. For context, Scarnose’s annual sales are ~₹10–12 crore. So yes, the ambition is an order of magnitude larger than the current P&L reality. In December 2024, the company also approved a name change to Devi Lifecare Ltd, increased authorised capital from ₹3.5 crore to ₹5.5 crore, and approved 21 lakh convertible warrants worth ₹23.5 crore. Translation: the company wants capital, scale, and a new identity—fast.

But numbers don’t care about ambition. They care about margins, cash flows, and returns. And that’s where the story gets… educational. Are these changes the foundation of a future growth arc, or a classic SME reinvention montage with background music but no box-office collection? Let’s dissect.

3. Business Model – WTF Do They Even Do?

On paper, Scarnose does everything. Manufacturing, trading, warehousing, clearing & forwarding, marketing, and brand building across pharmaceuticals, animal health, agriculture, hygiene, and consumer products. In reality, the revenue breakup for FY25 tells a simpler story: 99% sale of products, 1% interest on deposits. No fancy service income, no licensing windfalls—just selling stuff.

The expanded object clause lists:

• Pharma & Bulk Drugs (APIs, oncology, antibiotics, vaccines)
• Dosage Forms (tablets, capsules, syrups, injectables, creams)
• Consumer & Hygiene Products
• Fertilizers and agri products
• Traditional medicines across ayurvedic, unani, homeopathic lines

Now here’s the lazy-investor explanation: Scarnose is trying to position itself as a distribution-plus-trading platform that can plug into multiple high-demand sectors without committing heavy capex yet. The balance sheet supports this theory—fixed assets are just ₹0.04 crore as of Sep 2025, while other assets dominate. This is not a manufacturing-heavy setup today; it’s a trading/aggregation model with optionality.

Question for you: optionality is great, but how long does the market wait before asking for execution?

4. Financials Overview (Half-Yearly Locked)

Result Type Detected: Half Yearly Results
EPS Annualisation Rule Applied: EPS × 2

Performance Comparison Table (₹ crore, EPS in ₹)

Commentary: Revenue is volatile, margins are wafer-thin, and profits swing based on scale and other income. The company can be profitable, yes—but it’s not predictable yet. EBITDA margin for H1 FY26 is ~1.35%. That’s not a moat; that’s a speed bump.

Quick question: would you call this operating leverage or operating stress?

5.